In this study, we demonstrated that this p5RHH nucleotide delivery platform enables broad spectrum anti-NF-κB siRNA nanotherapy localizing to ATLL tumor sites that: suppress primary tumor growth, alter the natural history of subsequent tumor progression, and sensitize late-stage ATLL tumors to conventional chemotherapy. This evidence concerns the gene NFKB1 and neoplasm.